PMEL and melanoma: This approach enables defined peptide presentation as a fusion protein of HLA-A*0201 with either the CMV pp65 NLV peptide (on A431-NLV cells) or the control gp100 (melanoma-associated) IMDQVPFSV peptide (on A431-G209 cells).